drugset / Trial / NCT03736265
Carvedilol for Prevention of Esophageal Varices Progression
RandomizedParallel-groupSingle-blindPrevention
Summary
Carvedilol has been shown to be more potent in decreasing portal hypertension to propranolol. But the efficacy of carvedilol to delay the growth of esophageal varices in chronic hepatitis B patients was unclear.
Timeline
- Start
- 2017-10-09
- Primary completion
- 2022-11-30
- Completion
- 2022-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carvedilol | Other / unclassified | 12.5 mg | — |